Exosomes Market; by Workflow (Isolation Methods, Downstream Analysis); by Biomolecule Type (Non-coding RNAs, mRNA, Proteins, DNA fragments, Lipids); by Application (Cancer, Neurodegenerative Diseases, Cardiovascular Diseases, Infectious Diseases, Others); by Region (U.S., Canada, Mexico, Rest of North America, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) — Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027
Industry Trends
Exosomes are extracellular vesicles surrounded by membranes, which were first discovered in 1983. Exosomes typically have size of approximately 100 nm in diameter. Exosomes are produced in the endosomal compartment of most eukaryotic cells and can be defined as extracellular vesicles that are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. Exosomes have a lipid bilayer membrane and are responsible for communication between cells and transmission of macromolecules between cells. Moreover, exosomes are also considered to be responsible for transfer of proteins, lipids, messenger ribonucleic acid (mRNA), and other molecules and can also be used as vectors for drugs as they have cell membranes and have better tolerance by the host cell than synthetic polymers. Exosomes are nanovesicles composed of proteins, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) with huge potential for cancer diagnosis and play a key role in promoting cell to cell contact in the growth of cancer. This suppresses the immune function by inducing apoptosis of activated cytotoxic T cells, allowing development of tumors in the human body. Furthermore, exosomes also stimulate angiogenesis and migration which lead to metastasis. In addition, exosomes trigger apoptosis through tumor necrosis factor pathways in the anti-tumor immune cells. Healthcare professionals also use exosomes to diagnose cancer, which helps to profile genetic changes in tumors and also prevent the disease from spreading. Thus, increasing use of exosomes for research applications is aiding growth of the exosomes market.
Growth of the exosomes market is driven by factors such as growing funding for research in the life sciences, rapid rise in exosome-based therapeutic procedures, and high levels of cancer prevalence across the world. For instance, according to the International Agency for Research on Cancer (IARC), the number of new cancer cases globally were estimated to reach 18.1 million and 9.6 million deaths in 2018. Worldwide, approximately one in five men and one in six women develop cancer during their lifetime, whereas one in eight men and one in 11 women die from the disease. Globally, the total number of people who are alive within five years of a cancer diagnosis, known as the five year prevalence, is estimated to be 43.8 million. Europe, which has 9% of the world population, accounted for 23.4% of the global cancer cases and 20.3% of the cancer deaths. 13.3% of the global population lives in America, which accounted for 21.0% of incidence and 14.4% of mortality worldwide. Compared to other world regions, the proportion of cancer deaths in Asia and in Africa (57.3% and 7.3%, respectively) is more than the proportion of incident cases (48.4% and 5.8%, respectively), mainly because these regions have a higher frequency of certain types of cancers which are associated with poorer prognosis and higher death rates, in addition to limited access to timely diagnosis and treatment in many countries.
Exosomes have also been used for therapeutic applications. For example, exosomes extracted from cow's milk are used to supply therapeutic molecules against lung and breast cancer. Due to their small size, indigenous nature and the ability to cross biological barriers, exosomes derived from specific body sites are ideal candidates for anti-cancer vaccines and improved passive targeting. Thus, the rise in cancer cases is directly increasing the demand for exosomes for diagnostic as well as therapeutic purposes, which is further boosting the exosomes market.
Advantage of exosomes over regular cell-based treatments is another factor driving growth of the exosomes market. For example, use of exosomes helps to avoid problems related with cell transfer, where the cells have damaged or mutated DNA. Moreover, as most exosomes are small in size, they can easily move through capillaries, whereas, the whole cells are very large and cannot travel through capillaries, such as in lungs. Another benefit of exosomes, over regular cell based therapy is that mesenchymal stromal cells (MSCs) level can quickly diminish after transplant in cell based therapy, whereas exosomes can achieve a much higher dose. Exosomes can also be used to manage toxicity and immunogenicity complications resulting from biomaterial treatments such as nanoparticles.
Another factor contributing to growth of the exosomes market, is the increasing funding for life sciences research. For example, in the U.S., scientists from Johns Hopkins and others received more than US$ 940,000 in August 2019, to study cellular “packages” or extracellular vesicles that can be used to track disease status, diagnose disease, and possibly deliver medications. Moreover, NanoView Biosciences, a company working in the field of exosome characterization, was awarded a grant of US$ 750,000 by National Science Foundation Small Business Innovation Research in 2018. The funding will help the company continue and expand its research on completing development of the ExoView system, the company’s instrument and consumables platform that allows total characterization of exosomes and other extracellular vesicles.
Factors such as lack of skilled professionals and high costs of research may hamper growth of the exosomes market over the forecast period. On the other hand, untapped emerging markets such as China and India, increase in customized treatments and growing exosome-based treatments for various diseases are expected to present multiple opportunities for growth of the exosomes market in the near future. For example, as exosomes are enriched with small RNA, they play a key role in various physiological processes. They are involved in various processes of the brain including neuronal stress response, synaptic plasticity, neurogenesis, and cell-to-cell communication and thus can play a role in understanding mental disorders. Moreover, as exosomes can cross the blood–brain barrier, they may serve as accessible biomarkers of neural dysfunction. Thus, studying exosomes from brain, may provide a mechanistic view of the disease phenotype.
Workflow Outlook:
Based on the workflow, the exosomes market has been bifurcated into isolation methods and downstream analysis. Isolation methods are further segmented into ultracentrifugation, immunocapture on beads, precipitation, and filtration. The ultracentrifugation segment is estimated to hold the largest market share over the forecast period, due to easy availability of devices and reagents for this method. The downstream analysis is further segmented into cell surface marker analysis using flow cytometry, protein analysis using blotting & ELISA, RNA analysis with NGS & PCR, proteomic analysis using mass spectrometry, and others. The RNA analysis using NGS and PCR is expected to grow at the fastest rate over the forecast period, mainly due to technological developments, such as advanced computer programs and specialized equipment.
Biomolecule Type Outlook:
On the basis of type of biomolecule, the exosomes market has been classified into non-coding RNAs, mRNA, proteins, DNA fragments, and lipids. Non-coding RNAs (ncRNAs) are functional RNA molecules that are transcribed from mammalian genome that do not have protein coding capacity. These ncRNAs are also important in post-transcriptional regulation by acting as a signal, guide, scaffold, and decoy molecules in addition to their role in transcription. Increasing use of non-coding RNAs for various research activities coupled with the important roles they play in defining DNA methylation patterns, imprinting as well as chromatin remodeling is expected to boost the growth of this segment over the forecast period.
Application Outlook:
By way of applications, the exosomes market has been segmented into cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases, others. Cancer applications are currently dominating the exosomes market, mainly due to high number of cancer cases worldwide. Neurodegenerative diseases segment is expected to grow at a fast pace over the forecast period, mainly due to increasing research around these diseases using exosomes.
Regional Outlook:
North America dominated the exosomes market in 2018 due to considerable research activities and government funding for exosomes research in the U.S. For instance, the U.S. made the highest contributions with maximum citations of the publications pertaining to exosomes research from 1994 to 2017 present on the Web of Science database. However, Asia Pacific is expected to grow at the fastest pace over the forecast period owing to the presence of large population in this region, coupled with increasing levels of diseases. For example, according to the United Nations Population Fund, the current population of Asia Pacific region is approximately 4.3 billion, which is around 60% of the world’s population and the region contains two of the world’s most populous countries, namely, China and India.
In terms of revenue, the global exosomes market was valued at US$ 293.4 Mn in 2018 and is expected to reach US$ 1,237.1 Mn by 2027, growing at a CAGR of 17.6% over the forecast period. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.
Exosomes Market Revenue & Forecast, (US$ Million), 2015–2027
Competitive Landscape
The report provides both, qualitative and quantitative research of the exosomes market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
The primary global exosomes market participants include Fujifilm, Danaher, Lonza, Illumina, Inc., Qiagen, Thermo Fisher Scientific, Inc., Takara Bio Company, Malvern Instruments Ltd., Hitachi Chemical Diagnostics, Inc., Miltenyi Biotec, Novus Biologicals, Diagenode, New England Peptide, Inc., BioCat GmbH, MBL International Corporation, and BioVision Inc.
Global Exosomes Market:
- By Workflow
- Isolation Methods
- Ultracentrifugation
- Immunocapture on Beads
- Precipitation
- Filtration
- Downstream Analysis
- Cell Surface Marker Analysis Using Flow Cytometry
- Protein Analysis Using Blotting & ELISA
- RNA Analysis with NGS & PCR
- Proteomic Analysis using Mass Spectrometry
- Others
- Isolation Methods
- By Biomolecule Type
- Non-coding RNAs
- mRNA
- Proteins
- DNA Fragments
- Lipids
- By Disease Indication
- Cancer
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Others
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Exosomes Market
6. Market Synopsis:
Exosomes Market
7. Exosomes Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Exosomes Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Exosomes Market
7.6. Porter’s
Five Force Analysis
8. Global Exosomes Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Exosomes Market Revenue (US$ Mn)
8.2. Global
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
8.2.1. Isolation
Methods (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Ultracentrifugation,
Immunocapture on Beads, Precipitation, Filtration)
8.2.1.1. Ultracentrifugation
8.2.1.2. Immunocapture
on Beads
8.2.1.3. Precipitation
8.2.1.4. Filtration
8.2.2. Downstream
Analysis (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Cell Surface Marker Analysis
Using Flow Cytometry, Protein Analysis Using Blotting and ELISA, RNA Analysis
with NGS and PCR, Proteomic Analysis using Mass Spectrometry, Others)
8.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
8.2.2.2. Protein
Analysis Using Blotting and ELISA
8.2.2.3. RNA
Analysis with NGS and PCR
8.2.2.4. Proteomic
Analysis using Mass Spectrometry
8.2.2.5. Others
8.3. Key
Segment for Channeling Investments
8.3.1. By
Workflow
9. Global Exosomes Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
9.2.1. Non-coding
RNAs
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. mRNA
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Proteins
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. DNA
Fragments
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Lipids
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Biomolecule Type
10. Global Exosomes Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1. Cancer
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Neurodegenerative
Diseases
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Cardiovascular
Diseases
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Infectious
Diseases
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2013 – 2018
10.2.5.3. Market
Forecast, 2019 – 2027
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2013 – 2018
10.2.5.5.1.2. Market
Forecast, 2019 – 2027
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2013 – 2018
10.2.5.5.2.2. Market
Forecast, 2019 – 2027
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2013 – 2018
10.2.5.5.3.2. Market
Forecast, 2019 – 2027
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2013 – 2018
10.2.5.5.4.2. Market
Forecast, 2019 – 2027
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2013 – 2018
10.2.5.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Application
11. North America Exosomes Market Analysis and Forecasts, 2019 -
2027
11.1. Overview
11.1.1. North
America Exosomes Market Revenue (US$ Mn)
11.2. North
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
11.2.1. Isolation
Methods
11.2.1.1. Ultracentrifugation
11.2.1.2. Immunocapture
on Beads
11.2.1.3. Precipitation
11.2.1.4. Filtration
11.2.2. Downstream
Analysis
11.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
11.2.2.2. Protein
Analysis Using Blotting and ELISA
11.2.2.3. RNA
Analysis with NGS and PCR
11.2.2.4. Proteomic
Analysis using Mass Spectrometry
11.2.2.5. Others
11.3. North
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
11.3.1. Non-coding
RNAs
11.3.2. mRNA
11.3.3. Proteins
11.3.4. DNA
Fragments
11.3.5. Lipids
11.4. North
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
11.4.1. Cancer
11.4.2. Neurodegenerative
Diseases
11.4.3. Cardiovascular
Diseases
11.4.4. Infectious
Diseases
11.4.5. Others
11.5. North
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
11.5.1.1.1. Isolation
Methods
11.5.1.1.1.1. Ultracentrifugation
11.5.1.1.1.2. Immunocapture
on Beads
11.5.1.1.1.3. Precipitation
11.5.1.1.1.4. Filtration
11.5.1.1.2. Downstream
Analysis
11.5.1.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
11.5.1.1.2.2. Protein
Analysis Using Blotting and ELISA
11.5.1.1.2.3. RNA
Analysis with NGS and PCR
11.5.1.1.2.4. Proteomic
Analysis using Mass Spectrometry
11.5.1.1.2.5. Others
11.5.1.2. U.S
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
11.5.1.2.1. Non-coding
RNAs
11.5.1.2.2. mRNA
11.5.1.2.3. Proteins
11.5.1.2.4. DNA
Fragments
11.5.1.2.5. Lipids
11.5.1.3. U.S
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.3.1. Cancer
11.5.1.3.2. Neurodegenerative
Diseases
11.5.1.3.3. Cardiovascular
Diseases
11.5.1.3.4. Infectious
Diseases
11.5.1.3.5. Others
11.5.2. Canada
11.5.2.1. Canada
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
11.5.2.1.1. Isolation
Methods
11.5.2.1.1.1. Ultracentrifugation
11.5.2.1.1.2. Immunocapture
on Beads
11.5.2.1.1.3. Precipitation
11.5.2.1.1.4. Filtration
11.5.2.1.2. Downstream
Analysis
11.5.2.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
11.5.2.1.2.2. Protein
Analysis Using Blotting and ELISA
11.5.2.1.2.3. RNA
Analysis with NGS and PCR
11.5.2.1.2.4. Proteomic
Analysis using Mass Spectrometry
11.5.2.1.2.5. Others
11.5.2.2. Canada
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
11.5.2.2.1. Non-coding
RNAs
11.5.2.2.2. mRNA
11.5.2.2.3. Proteins
11.5.2.2.4. DNA
Fragments
11.5.2.2.5. Lipids
11.5.2.3. Canada
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.3.1. Cancer
11.5.2.3.2. Neurodegenerative
Diseases
11.5.2.3.3. Cardiovascular
Diseases
11.5.2.3.4. Infectious
Diseases
11.5.2.3.5. Others
11.5.3. Mexico
11.5.3.1. Mexico
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
11.5.3.1.1. Isolation
Methods
11.5.3.1.1.1. Ultracentrifugation
11.5.3.1.1.2. Immunocapture
on Beads
11.5.3.1.1.3. Precipitation
11.5.3.1.1.4. Filtration
11.5.3.1.2. Downstream
Analysis
11.5.3.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
11.5.3.1.2.2. Protein
Analysis Using Blotting and ELISA
11.5.3.1.2.3. RNA
Analysis with NGS and PCR
11.5.3.1.2.4. Proteomic
Analysis using Mass Spectrometry
11.5.3.1.2.5. Others
11.5.3.2. Mexico
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
11.5.3.2.1. Non-coding
RNAs
11.5.3.2.2. mRNA
11.5.3.2.3. Proteins
11.5.3.2.4. DNA
Fragments
11.5.3.2.5. Lipids
11.5.3.3. Mexico
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.3.1. Cancer
11.5.3.3.2. Neurodegenerative
Diseases
11.5.3.3.3. Cardiovascular
Diseases
11.5.3.3.4. Infectious
Diseases
11.5.3.3.5. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
11.5.4.1.1. Isolation
Methods
11.5.4.1.1.1. Ultracentrifugation
11.5.4.1.1.2. Immunocapture
on Beads
11.5.4.1.1.3. Precipitation
11.5.4.1.1.4. Filtration
11.5.4.1.2. Downstream
Analysis
11.5.4.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
11.5.4.1.2.2. Protein
Analysis Using Blotting and ELISA
11.5.4.1.2.3. RNA
Analysis with NGS and PCR
11.5.4.1.2.4. Proteomic
Analysis using Mass Spectrometry
11.5.4.1.2.5. Others
11.5.4.2. Rest
of North America Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule
Type
11.5.4.2.1. Non-coding
RNAs
11.5.4.2.2. mRNA
11.5.4.2.3. Proteins
11.5.4.2.4. DNA
Fragments
11.5.4.2.5. Lipids
11.5.4.3. Rest
of North America Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.3.1. Cancer
11.5.4.3.2. Neurodegenerative
Diseases
11.5.4.3.3. Cardiovascular
Diseases
11.5.4.3.4. Infectious
Diseases
11.5.4.3.5. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Workflow
11.6.3. By
Biomolecule Type
11.6.4. By
Application
12. Europe Exosomes Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Europe
Exosomes Market Revenue (US$ Mn)
12.2. Europe
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.2.1. Isolation
Methods
12.2.1.1. Ultracentrifugation
12.2.1.2. Immunocapture
on Beads
12.2.1.3. Precipitation
12.2.1.4. Filtration
12.2.2. Downstream
Analysis
12.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.2.2.2. Protein
Analysis Using Blotting and ELISA
12.2.2.3. RNA
Analysis with NGS and PCR
12.2.2.4. Proteomic
Analysis using Mass Spectrometry
12.2.2.5. Others
12.3. Europe
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.3.1. Non-coding
RNAs
12.3.2. mRNA
12.3.3. Proteins
12.3.4. DNA
Fragments
12.3.5. Lipids
12.4. Europe
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1. Cancer
12.4.2. Neurodegenerative
Diseases
12.4.3. Cardiovascular
Diseases
12.4.4. Infectious
Diseases
12.4.5. Others
12.5. Europe
Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.1.1.1. Isolation
Methods
12.5.1.1.1.1. Ultracentrifugation
12.5.1.1.1.2. Immunocapture
on Beads
12.5.1.1.1.3. Precipitation
12.5.1.1.1.4. Filtration
12.5.1.1.2. Downstream
Analysis
12.5.1.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.1.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.1.1.2.3. RNA
Analysis with NGS and PCR
12.5.1.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.1.1.2.5. Others
12.5.1.2. France
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.1.2.1. Non-coding
RNAs
12.5.1.2.2. mRNA
12.5.1.2.3. Proteins
12.5.1.2.4. DNA
Fragments
12.5.1.2.5. Lipids
12.5.1.3. France
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.3.1. Cancer
12.5.1.3.2. Neurodegenerative
Diseases
12.5.1.3.3. Cardiovascular
Diseases
12.5.1.3.4. Infectious
Diseases
12.5.1.3.5. Others
12.5.2. The UK
12.5.2.1. The
UK Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.2.1.1. Isolation
Methods
12.5.2.1.1.1. Ultracentrifugation
12.5.2.1.1.2. Immunocapture
on Beads
12.5.2.1.1.3. Precipitation
12.5.2.1.1.4. Filtration
12.5.2.1.2. Downstream
Analysis
12.5.2.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.2.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.2.1.2.3. RNA
Analysis with NGS and PCR
12.5.2.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.2.1.2.5. Others
12.5.2.2. The
UK Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.2.2.1. Non-coding
RNAs
12.5.2.2.2. mRNA
12.5.2.2.3. Proteins
12.5.2.2.4. DNA
Fragments
12.5.2.2.5. Lipids
12.5.2.3. The
UK Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.3.1. Cancer
12.5.2.3.2. Neurodegenerative
Diseases
12.5.2.3.3. Cardiovascular
Diseases
12.5.2.3.4. Infectious
Diseases
12.5.2.3.5. Others
12.5.3. Spain
12.5.3.1. Spain
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.3.1.1. Isolation
Methods
12.5.3.1.1.1. Ultracentrifugation
12.5.3.1.1.2. Immunocapture
on Beads
12.5.3.1.1.3. Precipitation
12.5.3.1.1.4. Filtration
12.5.3.1.2. Downstream
Analysis
12.5.3.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.3.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.3.1.2.3. RNA
Analysis with NGS and PCR
12.5.3.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.3.1.2.5. Others
12.5.3.2. Spain
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.3.2.1. Non-coding
RNAs
12.5.3.2.2. mRNA
12.5.3.2.3. Proteins
12.5.3.2.4. DNA
Fragments
12.5.3.2.5. Lipids
12.5.3.3. Spain
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.3.1. Cancer
12.5.3.3.2. Neurodegenerative
Diseases
12.5.3.3.3. Cardiovascular
Diseases
12.5.3.3.4. Infectious
Diseases
12.5.3.3.5. Others
12.5.4. Germany
12.5.4.1. Germany
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.4.1.1. Isolation
Methods
12.5.4.1.1.1. Ultracentrifugation
12.5.4.1.1.2. Immunocapture
on Beads
12.5.4.1.1.3. Precipitation
12.5.4.1.1.4. Filtration
12.5.4.1.2. Downstream
Analysis
12.5.4.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.4.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.4.1.2.3. RNA
Analysis with NGS and PCR
12.5.4.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.4.1.2.5. Others
12.5.4.2. Germany
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.4.2.1. Non-coding
RNAs
12.5.4.2.2. mRNA
12.5.4.2.3. Proteins
12.5.4.2.4. DNA
Fragments
12.5.4.2.5. Lipids
12.5.4.3. Germany
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.3.1. Cancer
12.5.4.3.2. Neurodegenerative
Diseases
12.5.4.3.3. Cardiovascular
Diseases
12.5.4.3.4. Infectious
Diseases
12.5.4.3.5. Others
12.5.5. Italy
12.5.5.1. Italy
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.5.1.1. Isolation
Methods
12.5.5.1.1.1. Ultracentrifugation
12.5.5.1.1.2. Immunocapture
on Beads
12.5.5.1.1.3. Precipitation
12.5.5.1.1.4. Filtration
12.5.5.1.2. Downstream
Analysis
12.5.5.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.5.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.5.1.2.3. RNA
Analysis with NGS and PCR
12.5.5.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.5.1.2.5. Others
12.5.5.2. Italy
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.5.2.1. Non-coding
RNAs
12.5.5.2.2. mRNA
12.5.5.2.3. Proteins
12.5.5.2.4. DNA
Fragments
12.5.5.2.5. Lipids
12.5.5.3. Italy
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.3.1. Cancer
12.5.5.3.2. Neurodegenerative
Diseases
12.5.5.3.3. Cardiovascular
Diseases
12.5.5.3.4. Infectious
Diseases
12.5.5.3.5. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.6.1.1. Isolation
Methods
12.5.6.1.1.1. Ultracentrifugation
12.5.6.1.1.2. Immunocapture
on Beads
12.5.6.1.1.3. Precipitation
12.5.6.1.1.4. Filtration
12.5.6.1.2. Downstream
Analysis
12.5.6.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.6.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.6.1.2.3. RNA
Analysis with NGS and PCR
12.5.6.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.6.1.2.5. Others
12.5.6.2. Nordic
Countries Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.6.2.1. Non-coding
RNAs
12.5.6.2.2. mRNA
12.5.6.2.3. Proteins
12.5.6.2.4. DNA
Fragments
12.5.6.2.5. Lipids
12.5.6.3. Nordic
Countries Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.3.1. Cancer
12.5.6.3.2. Neurodegenerative
Diseases
12.5.6.3.3. Cardiovascular
Diseases
12.5.6.3.4. Infectious
Diseases
12.5.6.3.5. Others
12.5.6.4. Nordic
Countries Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.7.1.1. Isolation
Methods
12.5.7.1.1.1. Ultracentrifugation
12.5.7.1.1.2. Immunocapture
on Beads
12.5.7.1.1.3. Precipitation
12.5.7.1.1.4. Filtration
12.5.7.1.2. Downstream
Analysis
12.5.7.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.7.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.7.1.2.3. RNA
Analysis with NGS and PCR
12.5.7.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.7.1.2.5. Others
12.5.7.2. Benelux
Union Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.7.2.1. Non-coding
RNAs
12.5.7.2.2. mRNA
12.5.7.2.3. Proteins
12.5.7.2.4. DNA
Fragments
12.5.7.2.5. Lipids
12.5.7.3. Benelux
Union Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.3.1. Cancer
12.5.7.3.2. Neurodegenerative
Diseases
12.5.7.3.3. Cardiovascular
Diseases
12.5.7.3.4. Infectious
Diseases
12.5.7.3.5. Others
12.5.7.4. Benelux
Union Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
12.5.8.1.1. Isolation
Methods
12.5.8.1.1.1. Ultracentrifugation
12.5.8.1.1.2. Immunocapture
on Beads
12.5.8.1.1.3. Precipitation
12.5.8.1.1.4. Filtration
12.5.8.1.2. Downstream
Analysis
12.5.8.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
12.5.8.1.2.2. Protein
Analysis Using Blotting and ELISA
12.5.8.1.2.3. RNA
Analysis with NGS and PCR
12.5.8.1.2.4. Proteomic
Analysis using Mass Spectrometry
12.5.8.1.2.5. Others
12.5.8.2. Rest
of Europe Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
12.5.8.2.1. Non-coding
RNAs
12.5.8.2.2. mRNA
12.5.8.2.3. Proteins
12.5.8.2.4. DNA
Fragments
12.5.8.2.5. Lipids
12.5.8.3. Rest
of Europe Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.3.1. Cancer
12.5.8.3.2. Neurodegenerative
Diseases
12.5.8.3.3. Cardiovascular
Diseases
12.5.8.3.4. Infectious
Diseases
12.5.8.3.5. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By Country
12.6.2. By
Workflow
12.6.3. By
Biomolecule Type
12.6.4. By
Application
13. Asia Pacific Exosomes Market Analysis and Forecasts, 2019 -
2027
13.1. Overview
13.1.1. Asia
Pacific Exosomes Market Revenue (US$ Mn)
13.2. Asia
Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.2.1. Isolation
Methods
13.2.1.1. Ultracentrifugation
13.2.1.2. Immunocapture
on Beads
13.2.1.3. Precipitation
13.2.1.4. Filtration
13.2.2. Downstream
Analysis
13.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.2.2.2. Protein
Analysis Using Blotting and ELISA
13.2.2.3. RNA
Analysis with NGS and PCR
13.2.2.4. Proteomic
Analysis using Mass Spectrometry
13.2.2.5. Others
13.3. Asia
Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.3.1. Non-coding
RNAs
13.3.2. mRNA
13.3.3. Proteins
13.3.4. DNA
Fragments
13.3.5. Lipids
13.4. Asia
Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1. Cancer
13.4.2. Neurodegenerative
Diseases
13.4.3. Cardiovascular
Diseases
13.4.4. Infectious
Diseases
13.4.5. Others
13.5. Asia
Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.1.1.1. Isolation
Methods
13.5.1.1.1.1. Ultracentrifugation
13.5.1.1.1.2. Immunocapture
on Beads
13.5.1.1.1.3. Precipitation
13.5.1.1.1.4. Filtration
13.5.1.1.2. Downstream
Analysis
13.5.1.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.1.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.1.1.2.3. RNA
Analysis with NGS and PCR
13.5.1.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.1.1.2.5. Others
13.5.1.2. China
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.1.2.1. Non-coding
RNAs
13.5.1.2.2. mRNA
13.5.1.2.3. Proteins
13.5.1.2.4. DNA
Fragments
13.5.1.2.5. Lipids
13.5.1.3. China
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.3.1. Cancer
13.5.1.3.2. Neurodegenerative
Diseases
13.5.1.3.3. Cardiovascular
Diseases
13.5.1.3.4. Infectious
Diseases
13.5.1.3.5. Others
13.5.2. Japan
13.5.2.1. Japan
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.2.1.1. Isolation
Methods
13.5.2.1.1.1. Ultracentrifugation
13.5.2.1.1.2. Immunocapture
on Beads
13.5.2.1.1.3. Precipitation
13.5.2.1.1.4. Filtration
13.5.2.1.2. Downstream
Analysis
13.5.2.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.2.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.2.1.2.3. RNA
Analysis with NGS and PCR
13.5.2.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.2.1.2.5. Others
13.5.2.2. Japan
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.2.2.1. Non-coding
RNAs
13.5.2.2.2. mRNA
13.5.2.2.3. Proteins
13.5.2.2.4. DNA
Fragments
13.5.2.2.5. Lipids
13.5.2.3. Japan
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.3.1. Cancer
13.5.2.3.2. Neurodegenerative
Diseases
13.5.2.3.3. Cardiovascular
Diseases
13.5.2.3.4. Infectious
Diseases
13.5.2.3.5. Others
13.5.3. India
13.5.3.1. India
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.3.1.1. Isolation
Methods
13.5.3.1.1.1. Ultracentrifugation
13.5.3.1.1.2. Immunocapture
on Beads
13.5.3.1.1.3. Precipitation
13.5.3.1.1.4. Filtration
13.5.3.1.2. Downstream
Analysis
13.5.3.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.3.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.3.1.2.3. RNA
Analysis with NGS and PCR
13.5.3.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.3.1.2.5. Others
13.5.3.2. India
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.3.2.1. Non-coding
RNAs
13.5.3.2.2. mRNA
13.5.3.2.3. Proteins
13.5.3.2.4. DNA
Fragments
13.5.3.2.5. Lipids
13.5.3.3. India
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.3.1. Cancer
13.5.3.3.2. Neurodegenerative
Diseases
13.5.3.3.3. Cardiovascular
Diseases
13.5.3.3.4. Infectious
Diseases
13.5.3.3.5. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.4.1.1. Isolation
Methods
13.5.4.1.1.1. Ultracentrifugation
13.5.4.1.1.2. Immunocapture
on Beads
13.5.4.1.1.3. Precipitation
13.5.4.1.1.4. Filtration
13.5.4.1.2. Downstream
Analysis
13.5.4.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.4.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.4.1.2.3. RNA
Analysis with NGS and PCR
13.5.4.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.4.1.2.5. Others
13.5.4.2. New
Zealand Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.4.2.1. Non-coding
RNAs
13.5.4.2.2. mRNA
13.5.4.2.3. Proteins
13.5.4.2.4. DNA
Fragments
13.5.4.2.5. Lipids
13.5.4.3. New
Zealand Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.3.1. Cancer
13.5.4.3.2. Neurodegenerative
Diseases
13.5.4.3.3. Cardiovascular
Diseases
13.5.4.3.4. Infectious
Diseases
13.5.4.3.5. Others
13.5.5. Australia
13.5.5.1. Australia
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.5.1.1. Isolation
Methods
13.5.5.1.1.1. Ultracentrifugation
13.5.5.1.1.2. Immunocapture
on Beads
13.5.5.1.1.3. Precipitation
13.5.5.1.1.4. Filtration
13.5.5.1.2. Downstream
Analysis
13.5.5.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.5.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.5.1.2.3. RNA
Analysis with NGS and PCR
13.5.5.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.5.1.2.5. Others
13.5.5.2. Australia
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.5.2.1. Non-coding
RNAs
13.5.5.2.2. mRNA
13.5.5.2.3. Proteins
13.5.5.2.4. DNA
Fragments
13.5.5.2.5. Lipids
13.5.5.3. Australia
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.3.1. Cancer
13.5.5.3.2. Neurodegenerative
Diseases
13.5.5.3.3. Cardiovascular
Diseases
13.5.5.3.4. Infectious
Diseases
13.5.5.3.5. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.6.1.1. Isolation
Methods
13.5.6.1.1.1. Ultracentrifugation
13.5.6.1.1.2. Immunocapture
on Beads
13.5.6.1.1.3. Precipitation
13.5.6.1.1.4. Filtration
13.5.6.1.2. Downstream
Analysis
13.5.6.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.6.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.6.1.2.3. RNA
Analysis with NGS and PCR
13.5.6.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.6.1.2.5. Others
13.5.6.2. South
Korea Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.6.2.1. Non-coding
RNAs
13.5.6.2.2. mRNA
13.5.6.2.3. Proteins
13.5.6.2.4. DNA
Fragments
13.5.6.2.5. Lipids
13.5.6.3. South
Korea Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.3.1. Cancer
13.5.6.3.2. Neurodegenerative
Diseases
13.5.6.3.3. Cardiovascular
Diseases
13.5.6.3.4. Infectious
Diseases
13.5.6.3.5. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.7.1.1. Isolation
Methods
13.5.7.1.1.1. Ultracentrifugation
13.5.7.1.1.2. Immunocapture
on Beads
13.5.7.1.1.3. Precipitation
13.5.7.1.1.4. Filtration
13.5.7.1.2. Downstream
Analysis
13.5.7.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.7.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.7.1.2.3. RNA
Analysis with NGS and PCR
13.5.7.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.7.1.2.5. Others
13.5.7.2. Southeast
Asia Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
13.5.7.2.1. Non-coding
RNAs
13.5.7.2.2. mRNA
13.5.7.2.3. Proteins
13.5.7.2.4. DNA
Fragments
13.5.7.2.5. Lipids
13.5.7.3. Southeast
Asia Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.3.1. Cancer
13.5.7.3.2. Neurodegenerative
Diseases
13.5.7.3.3. Cardiovascular
Diseases
13.5.7.3.4. Infectious
Diseases
13.5.7.3.5. Others
13.5.7.4. Southeast
Asia Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
13.5.8.1.1. Isolation
Methods
13.5.8.1.1.1. Ultracentrifugation
13.5.8.1.1.2. Immunocapture
on Beads
13.5.8.1.1.3. Precipitation
13.5.8.1.1.4. Filtration
13.5.8.1.2. Downstream
Analysis
13.5.8.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
13.5.8.1.2.2. Protein
Analysis Using Blotting and ELISA
13.5.8.1.2.3. RNA
Analysis with NGS and PCR
13.5.8.1.2.4. Proteomic
Analysis using Mass Spectrometry
13.5.8.1.2.5. Others
13.5.8.2. Rest
of Asia Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule
Type
13.5.8.2.1. Non-coding
RNAs
13.5.8.2.2. mRNA
13.5.8.2.3. Proteins
13.5.8.2.4. DNA
Fragments
13.5.8.2.5. Lipids
13.5.8.3. Rest
of Asia Pacific Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.3.1. Cancer
13.5.8.3.2. Neurodegenerative
Diseases
13.5.8.3.3. Cardiovascular
Diseases
13.5.8.3.4. Infectious
Diseases
13.5.8.3.5. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Workflow
13.6.3. By
Biomolecule Type
13.6.4. By
Application
14. Middle East and Africa Exosomes Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Exosomes Market Revenue (US$ Mn)
14.2. Middle
East and Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.2.1. Isolation
Methods
14.2.1.1. Ultracentrifugation
14.2.1.2. Immunocapture
on Beads
14.2.1.3. Precipitation
14.2.1.4. Filtration
14.2.2. Downstream
Analysis
14.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.2.2.2. Protein
Analysis Using Blotting and ELISA
14.2.2.3. RNA
Analysis with NGS and PCR
14.2.2.4. Proteomic
Analysis using Mass Spectrometry
14.2.2.5. Others
14.3. Middle
East and Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule
Type
14.3.1. Non-coding
RNAs
14.3.2. mRNA
14.3.3. Proteins
14.3.4. DNA
Fragments
14.3.5. Lipids
14.4. Middle
East and Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1. Cancer
14.4.2. Neurodegenerative
Diseases
14.4.3. Cardiovascular
Diseases
14.4.4. Infectious
Diseases
14.4.5. Others
14.5. Middle East
and Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.5.1.1.1. Isolation
Methods
14.5.1.1.1.1. Ultracentrifugation
14.5.1.1.1.2. Immunocapture
on Beads
14.5.1.1.1.3. Precipitation
14.5.1.1.1.4. Filtration
14.5.1.1.2. Downstream
Analysis
14.5.1.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.1.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.1.1.2.3. RNA
Analysis with NGS and PCR
14.5.1.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.1.1.2.5. Others
14.5.1.2. Saudi
Arabia Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
14.5.1.2.1. Non-coding
RNAs
14.5.1.2.2. mRNA
14.5.1.2.3. Proteins
14.5.1.2.4. DNA
Fragments
14.5.1.2.5. Lipids
14.5.1.3. Saudi
Arabia Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.3.1. Cancer
14.5.1.3.2. Neurodegenerative
Diseases
14.5.1.3.3. Cardiovascular
Diseases
14.5.1.3.4. Infectious
Diseases
14.5.1.3.5. Others
14.5.2. UAE
14.5.2.1. UAE
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.5.2.1.1. Isolation
Methods
14.5.2.1.1.1. Ultracentrifugation
14.5.2.1.1.2. Immunocapture
on Beads
14.5.2.1.1.3. Precipitation
14.5.2.1.1.4. Filtration
14.5.2.1.2. Downstream
Analysis
14.5.2.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.2.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.2.1.2.3. RNA
Analysis with NGS and PCR
14.5.2.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.2.1.2.5. Others
14.5.2.2. UAE
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
14.5.2.2.1. Non-coding
RNAs
14.5.2.2.2. mRNA
14.5.2.2.3. Proteins
14.5.2.2.4. DNA
Fragments
14.5.2.2.5. Lipids
14.5.2.3. UAE
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.3.1. Cancer
14.5.2.3.2. Neurodegenerative
Diseases
14.5.2.3.3. Cardiovascular
Diseases
14.5.2.3.4. Infectious
Diseases
14.5.2.3.5. Others
14.5.3. Egypt
14.5.3.1. Egypt
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.5.3.1.1. Isolation
Methods
14.5.3.1.1.1. Ultracentrifugation
14.5.3.1.1.2. Immunocapture
on Beads
14.5.3.1.1.3. Precipitation
14.5.3.1.1.4. Filtration
14.5.3.1.2. Downstream
Analysis
14.5.3.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.3.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.3.1.2.3. RNA
Analysis with NGS and PCR
14.5.3.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.3.1.2.5. Others
14.5.3.2. Egypt
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
14.5.3.2.1. Non-coding
RNAs
14.5.3.2.2. mRNA
14.5.3.2.3. Proteins
14.5.3.2.4. DNA
Fragments
14.5.3.2.5. Lipids
14.5.3.3. Egypt
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.3.1. Cancer
14.5.3.3.2. Neurodegenerative
Diseases
14.5.3.3.3. Cardiovascular
Diseases
14.5.3.3.4. Infectious
Diseases
14.5.3.3.5. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.5.4.1.1. Isolation
Methods
14.5.4.1.1.1. Ultracentrifugation
14.5.4.1.1.2. Immunocapture
on Beads
14.5.4.1.1.3. Precipitation
14.5.4.1.1.4. Filtration
14.5.4.1.2. Downstream
Analysis
14.5.4.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.4.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.4.1.2.3. RNA
Analysis with NGS and PCR
14.5.4.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.4.1.2.5. Others
14.5.4.2. Kuwait
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
14.5.4.2.1. Non-coding
RNAs
14.5.4.2.2. mRNA
14.5.4.2.3. Proteins
14.5.4.2.4. DNA
Fragments
14.5.4.2.5. Lipids
14.5.4.3. Kuwait
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.3.1. Cancer
14.5.4.3.2. Neurodegenerative
Diseases
14.5.4.3.3. Cardiovascular
Diseases
14.5.4.3.4. Infectious
Diseases
14.5.4.3.5. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
14.5.5.1.1. Isolation
Methods
14.5.5.1.1.1. Ultracentrifugation
14.5.5.1.1.2. Immunocapture
on Beads
14.5.5.1.1.3. Precipitation
14.5.5.1.1.4. Filtration
14.5.5.1.2. Downstream
Analysis
14.5.5.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.5.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.5.1.2.3. RNA
Analysis with NGS and PCR
14.5.5.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.5.1.2.5. Others
14.5.5.2. South
Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
14.5.5.2.1. Non-coding
RNAs
14.5.5.2.2. mRNA
14.5.5.2.3. Proteins
14.5.5.2.4. DNA
Fragments
14.5.5.2.5. Lipids
14.5.5.3. South
Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.3.1. Cancer
14.5.5.3.2. Neurodegenerative
Diseases
14.5.5.3.3. Cardiovascular
Diseases
14.5.5.3.4. Infectious
Diseases
14.5.5.3.5. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By
Workflow
14.5.6.1.1. Isolation
Methods
14.5.6.1.1.1. Ultracentrifugation
14.5.6.1.1.2. Immunocapture
on Beads
14.5.6.1.1.3. Precipitation
14.5.6.1.1.4. Filtration
14.5.6.1.2. Downstream
Analysis
14.5.6.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
14.5.6.1.2.2. Protein
Analysis Using Blotting and ELISA
14.5.6.1.2.3. RNA
Analysis with NGS and PCR
14.5.6.1.2.4. Proteomic
Analysis using Mass Spectrometry
14.5.6.1.2.5. Others
14.5.6.2. Rest
of Middle East & Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By
Biomolecule Type
14.5.6.2.1. Non-coding
RNAs
14.5.6.2.2. mRNA
14.5.6.2.3. Proteins
14.5.6.2.4. DNA
Fragments
14.5.6.2.5. Lipids
14.5.6.3. Rest
of Middle East & Africa Exosomes Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.6.3.1. Cancer
14.5.6.3.2. Neurodegenerative
Diseases
14.5.6.3.3. Cardiovascular
Diseases
14.5.6.3.4. Infectious
Diseases
14.5.6.3.5. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Workflow
14.6.3. By
Biomolecule Type
14.6.4. By
Application
15. Latin America Exosomes Market Analysis and Forecasts, 2019 -
2027
15.1. Overview
15.1.1. Latin
America Exosomes Market Revenue (US$ Mn)
15.2. Latin
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
15.2.1. Isolation
Methods
15.2.1.1. Ultracentrifugation
15.2.1.2. Immunocapture
on Beads
15.2.1.3. Precipitation
15.2.1.4. Filtration
15.2.2. Downstream
Analysis
15.2.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
15.2.2.2. Protein
Analysis Using Blotting and ELISA
15.2.2.3. RNA
Analysis with NGS and PCR
15.2.2.4. Proteomic
Analysis using Mass Spectrometry
15.2.2.5. Others
15.3. Latin
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
15.3.1. Non-coding
RNAs
15.3.2. mRNA
15.3.3. Proteins
15.3.4. DNA
Fragments
15.3.5. Lipids
15.4. Latin
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Cancer
15.4.2. Neurodegenerative
Diseases
15.4.3. Cardiovascular
Diseases
15.4.4. Infectious
Diseases
15.4.5. Others
15.5. Latin
America Exosomes Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
15.5.1.1.1. Isolation
Methods
15.5.1.1.1.1. Ultracentrifugation
15.5.1.1.1.2. Immunocapture
on Beads
15.5.1.1.1.3. Precipitation
15.5.1.1.1.4. Filtration
15.5.1.1.2. Downstream
Analysis
15.5.1.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
15.5.1.1.2.2. Protein
Analysis Using Blotting and ELISA
15.5.1.1.2.3. RNA
Analysis with NGS and PCR
15.5.1.1.2.4. Proteomic
Analysis using Mass Spectrometry
15.5.1.1.2.5. Others
15.5.1.2. Brazil
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
15.5.1.2.1. Non-coding
RNAs
15.5.1.2.2. mRNA
15.5.1.2.3. Proteins
15.5.1.2.4. DNA
Fragments
15.5.1.2.5. Lipids
15.5.1.3. Brazil
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.3.1. Cancer
15.5.1.3.2. Neurodegenerative
Diseases
15.5.1.3.3. Cardiovascular
Diseases
15.5.1.3.4. Infectious
Diseases
15.5.1.3.5. Others
15.5.2. Argentina
15.5.2.1. Argentina
Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
15.5.2.1.1. Isolation
Methods
15.5.2.1.1.1. Ultracentrifugation
15.5.2.1.1.2. Immunocapture
on Beads
15.5.2.1.1.3. Precipitation
15.5.2.1.1.4. Filtration
15.5.2.1.2. Downstream
Analysis
15.5.2.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
15.5.2.1.2.2. Protein
Analysis Using Blotting and ELISA
15.5.2.1.2.3. RNA
Analysis with NGS and PCR
15.5.2.1.2.4. Proteomic
Analysis using Mass Spectrometry
15.5.2.1.2.5. Others
15.5.2.2. Argentina
Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule Type
15.5.2.2.1. Non-coding
RNAs
15.5.2.2.2. mRNA
15.5.2.2.3. Proteins
15.5.2.2.4. DNA
Fragments
15.5.2.2.5. Lipids
15.5.2.3. Argentina
Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.3.1. Cancer
15.5.2.3.2. Neurodegenerative
Diseases
15.5.2.3.3. Cardiovascular
Diseases
15.5.2.3.4. Infectious
Diseases
15.5.2.3.5. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Exosomes Market Revenue (US$ Mn) and Forecasts, By Workflow
15.5.3.1.1. Isolation
Methods
15.5.3.1.1.1. Ultracentrifugation
15.5.3.1.1.2. Immunocapture
on Beads
15.5.3.1.1.3. Precipitation
15.5.3.1.1.4. Filtration
15.5.3.1.2. Downstream
Analysis
15.5.3.1.2.1. Cell
Surface Marker Analysis Using Flow Cytometry
15.5.3.1.2.2. Protein
Analysis Using Blotting and ELISA
15.5.3.1.2.3. RNA
Analysis with NGS and PCR
15.5.3.1.2.4. Proteomic
Analysis using Mass Spectrometry
15.5.3.1.2.5. Others
15.5.3.2. Rest
of Latin America Exosomes Market Revenue (US$ Mn) and Forecasts, By Biomolecule
Type
15.5.3.2.1. Non-coding
RNAs
15.5.3.2.2. mRNA
15.5.3.2.3. Proteins
15.5.3.2.4. DNA
Fragments
15.5.3.2.5. Lipids
15.5.3.3. Rest
of Latin America Exosomes Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.3.1. Cancer
15.5.3.3.2. Neurodegenerative
Diseases
15.5.3.3.3. Cardiovascular
Diseases
15.5.3.3.4. Infectious
Diseases
15.5.3.3.5. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Workflow
15.6.3. By
Biomolecule Type
15.6.4. By
Application
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. BioCat
GmbH
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. BioVision
Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Danaher
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Diagenode
S.A.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Fujifilm
Holdings Corporation
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Hitachi
Chemical Diagnostics, Inc.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Illumina,
Inc.
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Lonza
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Malvern
Instruments Ltd
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. MBL
International Corporation
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Miltenyi
Biotec
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. New
England Peptide, Inc.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Novus
Biologicals
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. QIAGEN
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Takara
Bio Inc.
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Thermo
Fisher Scientific, Inc.
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT
Analysis
17.16.7. Business
Strategies
17.17. Other
Market Participants
Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
